Gut microbiome (GMB) biomarkers in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair alterations (HRRm) treated with PARP inhibitor (PARPi) therapy.

Steven Yip(University of Calgary), Pinaki Bose(University of Calgary), Kathy D. McCoy(University of Calgary), K. M. Tahsin Hassan Rahit(University of Calgary), Christina Ohland(University of Calgary), Tracy Jing Xu(University of Calgary), Michelle L. Dean(Alberta Health Services), Joseph D. Ruether, Amanda Williams Gibson(University of Calgary), Daniel Yick Chin Heng(University of Calgary), Vishnupriya Parpalli(University of Calgary), Nimira Alimohamed(University of Calgary), Olabisi Amuda-James(University of Calgary), Vishal Navani(Hunter Medical Research Institute)
Journal of Clinical Oncology
March 1, 2026
Cited by 0


Related Papers